1
Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia
Condition(s):Acute Myeloid LeukemiaLast Updated:April 29, 2022Recruiting
Cladribine: 144 Clinical Trials, Page 1 of 15
Hide Studies Not Open or Pending
2
Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)
Condition(s):Multiple SclerosisLast Updated:June 22, 2022Active, not recruiting
3
Cladribine Tablets After Treatment With Natalizumab (CLADRINA)
Condition(s):Multiple SclerosisLast Updated:July 29, 2022Recruiting
4
Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic Syndromes
Condition(s):Leukemia, Myeloid, Acute; Leukemia, Lymphoblastic, AcuteLast Updated:June 28, 2018Unknown status
5
A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine Tablets
Condition(s):Multiple SclerosisLast Updated:January 13, 2022Recruiting
6
Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis
Condition(s):Multiple Sclerosis; Multiple Sclerosis, Relapsing-RemittingLast Updated:October 4, 2021Recruiting
7
ChariotMS – Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis
Condition(s):Advanced Multiple Sclerosis; Progressive Multiple SclerosisLast Updated:June 10, 2022Recruiting
8
Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic Syndromes
Condition(s):Acute Myeloid Leukemia Myelodysplastic SyndromesLast Updated:May 6, 2021Not yet recruiting
9
A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)
Condition(s):Multiple SclerosisLast Updated:May 18, 2022Recruiting
10
A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS)
Condition(s):Multiple SclerosisLast Updated:July 20, 2022Active, not recruiting